Xie Jialong, Chen Shichun, Ding Shaobo
Department of Pharmacy, Dongguan People's Hospital, Dongguan, Guangdong, China.
Medicine (Baltimore). 2020 Apr;99(16):e19777. doi: 10.1097/MD.0000000000019777.
The injection of the traditional Chinese patent medicine salviae miltiorrhizae and ligustrazine hydrochloride injection (SMLHI) has been widely used in treatment of various diseases such as angina pectoris or ischemic stroke in China. We aim to evaluate the efficacy and safety of SMLHI for the treatment of perioperative period of fracture.
A systematic literature search was performed in seven medical databases from their inception until February 2019. 16 studies with randomized controlled trials, totaling 1589 patients, were included in this meta-analysis. The included studies were assessed by the cochrane risk of bias and analyzed by Review Manager 5.3 software.
The meta-analysis showed that SMLHI for the treatment of perioperative period of fracture was significantly better compared with the control group in terms of the total effective rate. The result showed that SMLHI could significantly reduce the risk of deep vein thrombosis and inflammatory cytokines. Furthermore, the result showed that SMLHI could significantly improve the coagulation function indexes such as prothrombin time, plasma fibrinogen and D-Dimer (P < .0001).
This meta-analysis demonstrated that SMLHI may be more effective and safe for the treatment of perioperative period of fracture. However, further and higher quality randomized controlled trials are required to prove treatment outcome.
中药丹参和盐酸川芎嗪注射液（SMLHI）在中国已广泛用于治疗各种疾病，如心绞痛或缺血性中风。我们旨在评估SMLHI治疗骨折围手术期的疗效和安全性。
对七个医学数据库从建库至2019年2月进行系统文献检索。本荟萃分析纳入16项随机对照试验研究，共1589例患者。纳入研究采用Cochrane偏倚风险评估，并使用Review Manager 5.3软件进行分析。
荟萃分析显示，在总有效率方面，SMLHI治疗骨折围手术期明显优于对照组。结果表明，SMLHI可显著降低深静脉血栓形成和炎性细胞因子的风险。此外，结果表明，SMLHI可显著改善凝血功能指标，如凝血酶原时间、血浆纤维蛋白原和D - 二聚体（P < 0.0001）。
本荟萃分析表明，SMLHI治疗骨折围手术期可能更有效且安全。然而，需要进一步开展更高质量的随机对照试验来证实治疗效果。
